CC
CLDX icon

Centiva Capital’s Celldex Therapeutics CLDX Stock Holding History

Centiva Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,303
Closed -$413K – 1190
2025
Q2 		$413K Buy
+20,303
New +$395K 0.01% 1049
2023
Q4 		– Sell
-9,727
Closed -$268K – 1846
2023
Q3 		$268K Buy
+9,727
New +$305K 0.01% 1236
2018
Q4 		– Sell
-8,115
Closed -$55K – 259
2018
Q3 		$55K Sell
8,115
-4,402
-35% -$30.8K ﹤0.01% 178
2018
Q2 		$95K Buy
+12,517
New +$167K 0.02% 84

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Centiva Capital's CLDX Position: Q3 2025 in Review

Centiva Capital sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 20,303 shares — an estimated $413K sold.

Centiva Capital first reported a position in CLDX in Q2 2018 and held it in 4 quarters. The position peaked at $413K in Q2 2025. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Centiva Capital reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 20,303 Celldex Therapeutics shares in Q3 2025, an estimated $413K.
  • Centiva Capital first reported a position in Celldex Therapeutics in Q2 2018 and held it in 4 quarters.
  • Centiva Capital's Celldex Therapeutics position peaked at $413K in Q2 2025.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.